Edition:
United Kingdom

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

6,295JPY
22 Nov 2017
Change (% chg)

¥-49 (-0.77%)
Prev Close
¥6,344
Open
¥6,395
Day's High
¥6,402
Day's Low
¥6,288
Volume
542,500
Avg. Vol
789,061
52-wk High
¥7,085
52-wk Low
¥5,496

Select another date:

Tue, Oct 31 2017

BRIEF-Eisai Co to invest about $8.8 mln at Vizag plant in India - Nikkei‍​

* Eisai co to invest about $8.8 million to install manufacturing equipment at Vizag plant in India - Nikkei‍​ Source text for Eikon: Further company coverage:

BRIEF-Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab

* Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab

BRIEF-Eisai Co signs agreement with Grupo Biotoscana granting GBT exclusive licensing rights

* Eisai Co - signed agreement with Grupo Biotoscana granting GBT exclusive licensing rights

BRIEF-FDA approves Eisai's Fycompa for use as monotherapy for the treatment of partial-onset seizures

* FDA approves Eisai's Fycompa® (perampanel) for use as monotherapy for the treatment of partial-onset seizures

BRIEF-Eisai submits supplemental new drug application to FDA for lenvatinib in first-line hepatocellular carcinoma

* Eisai submits supplemental new drug application to FDA for lenvatinib in first-line hepatocellular carcinoma

BRIEF-Oncology Venture and Eisai forge exclusive global license agreement for clinical stage oncology drug PARP inhibitor E7449 / 2X-121

* ‍Oncology Venture - Co entered into exclusive global license agreement with Eisai Inc. for Eisai's phase 2 parp inhibitor E7449 - now called 2X-121​

BRIEF-Oncology Venture Sweden and Eisai sign exclusive global license agreement

* ONCOLOGY VENTURE AND EISAI FORGE EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR CLINICAL STAGE ONCOLOGY DRUG PARP INHIBITOR E7449 / 2X-121 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF- R&I affirms Eisai's rating at "A+" and announces stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

BRIEF-Ewopharma announces commercial partnership with Eisai

* Ewopharma says it will commercialise Halaven (eribulin mesylate) in nine countries within European Union and in two countries outside of EU

Select another date: